The Next Chapter of Science
Technology Networks - February 16, 2024
Xingxing Zang, Ph.D., says chimeric antigen receptor (CAR)-immune cell therapy, particularly CAR-T therapy, is a major advancing field with potential to revolutionize cancer treatment, particularly for leukemia and lymphoma. Dr. Zang is a member of the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC), and professor of microbiology & immunology, of oncology, of medicine, and of urology, and the Louis Goldstein Swan Chair in Cancer Research at Einstein.